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Conclusions: In this series of patients undergoing TAVR and having sequential BNP
measurements, baseline BNP did not predict survival, but BNP decreasing by more than
2000 pg/ml 30 days after TAVR was a strong predictor of survival.
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Background: To serve as comparative data for percutaneous replacement, the purpose of
this study was to characterize the historical outcomes for aortic and mitral valve
replacement surgery in a large, nationally representative patient population.
Methods: Patients undergoing aortic or mitral valve replacement were identified from the
5% national Medicare data (1997-2009) using ICD-9-CM codes 35.21 to 35.24. The
subsequent rates of mortality, mechanical complications, infection, and valve re-
implantation/reoperation, and infective endocarditis were evaluated. Hospitalization
charges and reimbursements (in Jan 2011 dollars) for the index procedure were also
assessed.
Results: The patient cohort included 12,202 aortic bioprosthesis, 9,757 aortic
mechanical valves, 3,222 mitral bioprosthesis, and 4,401 mitral mechanical
valves. The ten-year Kaplan-Meier mortality, mechanical complication, infection,
re-implantation/reoperation, and infective endocarditis rates for aortic biopros-
thesis were 64.4%, 4.41%, 4.54%, 1.50%, and 8.34%, respectively, and for aortic
mechanical valves were 63.9%, 5.23%, 4.71%, 1.84%, and 9.08%, respectively.
The corresponding ten-year Kaplan-Meier rates for mitral bioprosthesis were
74.8%, 8.02%, 6.29%, 2.81%, and 12.90%, respectively, and for mitral mechan-
ical valves were 64.7%, 7.60%, 6.06%, 2.87%, and 12.24%, respectively. The
average hospitalization reimbursements for procedures involving aortic biopros-
theses, aortic mechanical valves, mitral bioprostheses, and mitral mechanical
valves were $54.3k, $54.6k, $64.1k, and $62.2k, respectively.
Conclusions: The crude risk of mortality and complications, as well as payer costs, were
found to be higher for mitral valve replacements compared with aortic valve replace-
ments. This study provides baseline data for evaluating the comparative effectiveness of
percutaneous valve replacement to “traditional” approaches, especially since the percu-
taneous approach may have inherently different levels of performance or expanded
indications.
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Background: Long-standing aortic stenosis (AS) causes left ventricular (LV)
dysfunction, which may improve after trans-catheter aortic valve implantation
(TAVI). The LV subendocardium is composed of longitudinal fibres which are
highly sensitive to ischaemia caused by high LV filling pressures. Measurement
of long axis systolic amplitude is an easy measure of subendocardial function. The
aim of this study was to assess the nature of subendocardial abnormalities in AS
and their response to TAVI.
Methods: We studied 46 consecutive patients (age 827 years) with severe AS
but no flow-limiting coronary artery disease, one week before and 6 months after
TAVI. LV ejection fraction (LVEF) was calculated using Simpsons biplane
methods. LV subendocardial dysfunction was studied from long axis M-mode
amplitude at the lateral, septal, and posterior sites. Systolic amplitide was
measured as displacement of the mitral ring between the q wave of the ECG to
aortic valve closure. Incoordination (post-ejection shortening: PES) was measured
as amplitude of further inward motion after aortic valve closure. LV diastolic
function was assessed by mitral filling velocities (early diastolic: E wave, and late
diastolic: A wave). Averaged values for lateral, septal, and posterior sites are
presented, and values were compared to 17 normal controls.
Results: In controls, LVEF was 657%, long axis systolic amplitude and velocity
were 143mm and 72cm/s, there was no PES, and E:A ratio was 1.00.3. In
patients before TAVI, LVEF, long axis systolic amplitide and velocities were
lower than controls (4619%, 6.52.1mm, 4.11.9cm/s respectively), PES was
present (31mm) and E:A was higher than controls (3.34.6, all p0.01). After
TAVI, LVEF did not change (4917%), but long axis systolic amplitide and
velocities increased (to 9.22.3mm, and 6.72.1cm/s); PES increased (to
52mm) and E:A ratio fell (to 2.11.4).
Conclusions: Relief of AS following TAVI causes improvement in LV subendo-
cardial function manifest as increased long axis systolic amplitude and velocity.
However reduction in LV-EDP also permits appearance of incoordination, with
associated abnormal diastolic function, that may require exclusion of epicardial
coronary obstruction.
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Background: Advances in cardiovascular care has a significant impact on changing the
landscape of valvular heart disease. Balloon aortic valvuloplasty (BAV) considered to be
of palliative role become of essential importance in the era of TAVI. Patients with severe
aortic stenosis and poor surgical candidacy not yet qualifying for TAVI still require BAV
as a main therapeutic tool. The hemodynamic stress of BAV on those with profound
ventricular dysfunction, however, requires circulatory assistance to permit periprocedural
survival.
Methods: We evaluated the short term safety and efficacy of using Impella left
ventricular assist device in extremely high-risk patient underoing aortic valvulo-
plasty procedure. 13 patients with severe critical aortic stenosis and multiple
co-morbidities underwent BAV at our institute, 53% patients had concomitant
coronary interventions out of which 38% had multivessel PCI . Because of
advanced age, multiple co-morbidities and poor cardiac reserve & hemodynamic
status, the BAV’s were supported with the Impella.We describe a technique in
which a single 14 french retrograde arterial access was obtained and after crossing
the aortic valve, a 0.035 J-wire with LV curve along with a 0.014 Impella wire
was left in the LV cavity. The impella device is primed and loaded on the 0.014
wire ready to go in case of a hemodynamic compromise. After balloon aortic
valvuloplasty with rapid ventricular pacing is done, the Impella LVAD is rapidly
railed into the LV for hemodynamic support.
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Patient Characteristics
Age (mean) 83.1 years	/ 10.1
Caucasians / African-Americans 84% / 16%
Gender % ( males / females ) 69 / 31
LVEF (mean) 15 %	/ 8%
Co-morbidities
Prior MI 62%
Prior PCI 38%
Diabetes 67%
PVD 64%
CKD ( IV/V) 46%
Prior CABG 28%
Co-morbidity based mortality Risk Scoring
STS – Mean Risk of Procedural Mortality 65%	/ 18.8 %
STS – mean Mortality or morbidity 87.1%	/ 23.7%
Mean EuroSCORE II predicted mortality 52.42%	/ 11.8%
Mean EUROSCORE predicted
mortality(logistic)
66.5%	/ 21%
Mean Parsonnet predicted 30 day mortality 38.9%	/ 13.3%
Aortic Valve Characteristics
AVA Mean Grad
Pre 0.55 45
Post 0.68 32
Results: All patients had uneventful BAVs with this form of Impella support.The
in-hospital mortality was 15% with mean hospital length of stay 6 days 	/ 3.
Conclusions: BAV supported by Impella LVAD in a group of high risk patients
with advanced age and poor cardiac reserve is feasible and efficacious.This
particular algorhythm permits intervention with only a single arterial access.
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Background: The approach of transcatheter aortic valve implantation (TAVI) is
primarily guided by the assessment of iliaco-femoral tract diameter. A minimal diameter
of 6mm of the transfemoral tract is required for transfemoral TAVI. Currently, projection
angiography (XA) and CT-angiography (CTA) are used interchangeably to evaluate
suitability of the iliaco-femoral tract. Discrepancies between XA and CTA remain to be
elucidated. We aim to reveal differences in iliaco-femoral tract diameters of TAVI
candidates assessed by XA and CTA.
Methods: Diameters of 273 prospectively collected iliacofemoral segments of 39 TAVI
candidates were analyzed on both XA and CTA by two observers. We determined the
interobserver agreement for both imaging modalities and the difference between XA and
CTA measurements.
Results: Diameters measured on CTA were on average smaller (mean 8.23.0 mm,
mean difference 1.89 mm [95%CI: 1.65-2.13mm; p0.001]). The interobserver agree-
ment was excellent (Pearson coefficient: 0.92 for XA and 0.93 for CTA). For 21% (8
patients) CTA based diameters would have resulted in withholding a transfemoral
procedure, whilst diameters measured on XA were larger than 6mm.
Conclusions: Diameters on CTA are significantly smaller than XA-based measurements,
which should be acknowledged when determining the TAVI approach. The cut-off value
of 6mm on XA may be lower for CTA.
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Background: We have previously shown that there is an increased rate of embolic cerebral
insults after transcatheter aortic valve implantation (TAVI). Cerebral microbleeds have been
identified as a marker for poor neurologic outcome. The aim of this study was to assess and
compare the rate of new periprocedural embolic cerebral insults and microbleeds in patients
after TAVI and surgical AVR by MRI and their respective clinical outcome.
Methods: 48 consecutive patients (18 male, 30 female, mean age 815 years, average log.
Euroscore 3210%) undergoing TAVI received a cranial MRI before and after the TAVI
procedure to detect new cerebral lesions. 44 consecutive patients (26 male, 18 female, mean
age 785 years, average log. Euroscore 1310%) undergoing surgical AVR also received a
baseline cerebral MRI scan preoperatively and MRI was repeated within 6 days after valve
implantation. MRI studies included axial diffusion weighted, T2 weighted, FLAIR-weighted
and T2 gradient echo sequences. Standardized clinical assessment of the neurologic status was
performed prior to aortic valve replacement and before discharge.
Results: In 63% of the TAVI patients new cerebral embolic lesions could be detected in the
postprocedural MRI. The maximal lesion size was  5mm in 10 patients,  10mm in 17
patients and 10mm in 3 patients. Despite the high incidence of morphologically detectable
lesions only a single patient developed relevant neurologic symptoms of a stroke. Within
patients after surgical AVR only 44% of the patients displayed new cerebral embolic lesions.
The maximal lesion size was 5mm in 10 patients, 10mm in 6 patients and 10mm in
3 patients. No clinically relevant strokes were seen in this group. In contrast, cerebral
microbleeds were only detected in 13% of the TAVI patients but in 64% of patients after
surgical AVR.
Conclusions: New embolic cerebral insults and microbleeds detected by MRI were seen
both patient groups (TAVI	surgical AVR). Patients after surgical AVR showed more
microbleeds, whereas patients after TAVI showed more embolic ischemic insults. However,
despite the high percentage of MRI detected lesions in both groups, relevant neurological
symptoms were very rare and mostly transitory.
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Background: The introduction of transcatheter aortic valve replacement (TAVR) has led
to a revival in balloon aortic valvuloplasty (BAV) as treatment for patients with severe
aortic stenosis.
Methods: A cohort of 472 patients underwent 538 BAV procedures. The cohort was
divided into two groups: Group I, 296 (55.0%) procedures before 2010 and Group II, 242
(45%) procedures after 2010. Successful BAV was defined as reduction 40% in the
mean gradient and/or increase in aortic valve area 40%. Clinical, hemodynamic, and
follow-up mortality data were collected.
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